U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Approval Year

Substance Class Structurally Diverse
Created
by admin
on Fri Jun 25 21:26:16 UTC 2021
Edited
by admin
on Fri Jun 25 21:26:16 UTC 2021
Source Materials Class ORGANISM
Source Materials Type VIRUS
Organism Family Retroviridae
Organism Genus Lentivirus
Organism Species Human immunodeficiency virus 1
Author NONE
Part WHOLE
Record UNII
859A956UY8
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
HUMAN IMMUNODEFICIENCY VIRUS TYPE 1
Common Name English
HIV-1
Common Name English
Code System Code Type Description
FDA UNII
859A956UY8
Created by admin on Fri Jun 25 21:26:16 UTC 2021 , Edited by admin on Fri Jun 25 21:26:16 UTC 2021
PRIMARY
Related Record Type Details
INHIBITOR->TARGET ORGANISM
Other
INHIBITOR->TARGET ORGANISM
INHIBITOR->TARGET ORGANISM
INHIBITOR->TARGET ORGANISM
The observation of gastrointestinal intolerability and the emergence of resistant virus led to the cessation of development activities in favor of compounds with improved antiviral profiles.
EC50
INHIBITOR->TARGET ORGANISM
INHIBITOR -> TARGET
INHIBITOR->TARGET ORGANISM
TARGET ORGANISM->INHIBITOR
TARGET ORGANISM->INHIBITOR
INHIBITOR->TARGET ORGANISM
INHIBITOR->TARGET ORGANISM
INHIBITOR->TARGET ORGANISM
IN-VITRO
INHIBITOR->TARGET ORGANISM
INHIBITOR->TARGET ORGANISM
INHIBITOR->TARGET ORGANISM
INHIBITOR->TARGET ORGANISM
INHIBITOR->TARGET ORGANISM
INHIBITOR->TARGET ORGANISM
TARGET ORGANISM->INHIBITOR
INHIBITOR -> TARGET
INHIBITOR->TARGET ORGANISM
INHIBITOR->TARGET ORGANISM
An Fc-aglycosylated, non–T-cell–depleting and CD4-specific humanized IgG1 derived from the parent murine B4, which binds to discontinuous, conformational epitopes on the HIV-receptor complex, including CD4 domain 1, and competitively blocks HIV entry
INHIBITOR->TARGET ORGANISM
INHIBITOR->TARGET ORGANISM
INHIBITOR->TARGET ORGANISM
EC50
INHIBITOR->TARGET ORGANISM
INHIBITOR->TARGET ORGANISM
Tipranavir (TPV) is a non-peptidic HIV-1 protease inhibitor that inhibits the virus-specific processing of the viral Gag and Gag-Pol polyproteins in HIV-1 infected cells, thus preventing formation of mature virions.
TARGET ORGANISM->INHIBITOR
INHIBITOR->TARGET ORGANISM
INHIBITOR->TARGET ORGANISM
INHIBITOR->TARGET ORGANISM
INHIBITOR->TARGET ORGANISM
INHIBITOR->TARGET ORGANISM
INHIBITOR->TARGET ORGANISM
INHIBITOR->TARGET ORGANISM
INHIBITOR->TARGET ORGANISM
INHIBITOR->TARGET ORGANISM
INHIBITOR->TARGET ORGANISM
INHIBITOR->TARGET ORGANISM
INHIBITOR->TARGET ORGANISM
INHIBITOR->TARGET ORGANISM
INHIBITOR->TARGET ORGANISM
TARGET ORGANISM->INHIBITOR
INHIBITOR->TARGET ORGANISM
INHIBITOR -> TARGET
INHIBITOR->TARGET ORGANISM
INHIBITOR->TARGET ORGANISM
INHIBITOR->TARGET ORGANISM
INHIBITOR->TARGET ORGANISM
INHIBITOR->TARGET ORGANISM
INHIBITOR->TARGET ORGANISM
INHIBITOR->TARGET ORGANISM
INHIBITOR->TARGET ORGANISM
INHIBITOR->TARGET ORGANISM
TARGET ORGANISM->INHIBITOR
TARGET ORGANISM->INHIBITOR
INHIBITOR->TARGET ORGANISM
INHIBITS BINDING
INHIBITOR->TARGET ORGANISM
TARGET ORGANISM->INHIBITOR
INHIBITOR->TARGET ORGANISM
EC50
INHIBITOR->TARGET ORGANISM
EC50
INHIBITOR->TARGET ORGANISM
The in vitro results showed that the EC50 of BILR 355 was 0.26 ng/ml (0.59 nM) against wild-type HIV-1 and ranged from 1.5 to 13 ng/ml (3.4 –29 nM) against clinically common single and double NNRTI mutations .
INHIBITOR->TARGET ORGANISM
INHIBITOR->TARGET ORGANISM
INHIBITOR->TARGET ORGANISM
TARGET ORGANISM->INHIBITOR
INHIBITOR->TARGET ORGANISM
TARGET ORGANISM->INHIBITOR
INHIBITOR->TARGET ORGANISM
INHIBITOR->TARGET ORGANISM
INHIBITOR->TARGET ORGANISM
INHIBITOR -> TARGET
INHIBITOR->TARGET ORGANISM